Dietary magnesium intake and fracture risk: data from a large prospective study

Veronese, Nicola; Stubbs, Brendon; Solmi, Marco; Noale, Marianna; Vaona, Alberto; Demurtas, Jacopo; Maggi, Stefania

doi:10.1017/s0007114517001350

Cited by 55 publications

(45 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, magnesium supplements have been shown to improve BMD in osteoporotic women [ 98 , 99 ] and in young people [ 100 – 102 ]. Moreover, high dietary magnesium intake reduced prospectively the risk of osteoporotic fractures in middle-aged men and women [ 103 ]. The relationship between magnesium and bone health can be explained by different mechanisms.…”

Section: Hypomagnesemia and Endocrine Diseasesmentioning

confidence: 99%

Magnesium and Human Health: Perspectives and Research Directions

Alawi

Majoni

Falhammar

2018

International Journal of Endocrinology

318

223

View full text Add to dashboard Cite

Magnesium is the fourth most abundant cation in the body. It has several functions in the human body including its role as a cofactor for more than 300 enzymatic reactions. Several studies have shown that hypomagnesemia is a common electrolyte derangement in clinical setting especially in patients admitted to intensive care unit where it has been found to be associated with increase mortality and hospital stay. Hypomagnesemia can be caused by a wide range of inherited and acquired diseases. It can also be a side effect of several medications. Many studies have reported that reduced levels of magnesium are associated with a wide range of chronic diseases. Magnesium can play important therapeutic and preventive role in several conditions such as diabetes, osteoporosis, bronchial asthma, preeclampsia, migraine, and cardiovascular diseases. This review is aimed at comprehensively collating the current available published evidence and clinical correlates of magnesium disorders.

show abstract

Section: Hypomagnesemia and Endocrine Diseasesmentioning

confidence: 99%

Magnesium and Human Health: Perspectives and Research Directions

Alawi

Majoni

Falhammar

2018

International Journal of Endocrinology

318

223

View full text Add to dashboard Cite

show abstract

“…No randomized studies evaluating the effect of magnesium on bone disease are available, but small-size studies have associated low serum magnesium levels with osteoporosis [35,36]. In older subjects, a low intake of magnesium causes excessive calcium release from the bone, which further worsens bone fragility and increases the risks of fractures and falls [37]. A cross-sectional analysis of a cohort of subjects in the UK evaluating the influence of dietary magnesium and potassium intakes on bone density and fracture risk found a lower hip fracture risk in both men and women with a higher intake of these minerals, but these results did not hold after adjustment for multiple testing [38].…”

Section: Other Mineralsmentioning

confidence: 99%

Nutrients and Dietary Patterns Related to Osteoporosis

2020

View full text Add to dashboard Cite

Osteoporosis is a common chronic disease characterized by a decrease in bone mineral density, impaired bone strength, and an increased risk of fragility fractures. Fragility fractures are associated with significant morbidity, mortality and disability and are a major public health problem worldwide. The influence of nutritional factors on the development and progression of this disease can be significant and is not yet well established. Calcium intake and vitamin D status are considered to be essential for bone metabolism homeostasis. However, some recent studies have questioned the usefulness of calcium and vitamin D supplements in decreasing the risk of fractures. The adequate intake of protein, vegetables and other nutrients is also of interest, and recommendations have been established by expert consensus and clinical practice guidelines. It is important to understand the influence of nutrients not only in isolation but also in the context of a dietary pattern, which is a complex mixture of nutrients. In this review, we evaluate the available scientific evidence for the effects of the main dietary patterns on bone health. Although some dietary patterns seem to have beneficial effects, more studies are needed to fully elucidate the true influence of diet on bone fragility.

show abstract

“…Thus, in this study, we prescribed ALF instead of Denotas ® Chewable supplementation; however, it is recommended to use Denotas ® Chewable instead of active vitamin D supplementation since Denotas ® Chewable also includes Mg, and denosumab might have decreased the serum Mg level when denosumab is used for a long time. In addition, Veronese et al have very recently reported that dietary Mg intake has a protective effect for and lower risk of future osteoporotic fractures [ 32 ]. Collectively, a prospective study will be required to see whether or not Mg supplementation affects bone metabolism and fracture occurrence in a large cohort study.…”

Section: Discussionmentioning

confidence: 99%

Changes of Bone-Related Minerals during Denosumab Administration in Post-Menopausal Osteoporotic Patients

2017

View full text Add to dashboard Cite

Objectives: This retrospective study included 21 patients with primary osteoporosis who were treated with the anti-resorption drug, denosumab. To date, there has been no detailed report on the changes of bone-related minerals after anti-resorption drug therapy. Methods: Twenty-one post-menopausal females were retrospectively enrolled. Serum zinc (Zn), magnesium (Mg), iron (Fe), copper (Cu), grip strength, and estimated glomerular filtration rate (eGFR) were examined at one week and 1, 2, 4, 6, 8, 10, and 12 months. Lumbar spine (L1-4) bone mineral density (L-BMD) and bilateral total hip BMD (H-BMD) were examined before and at 4, 8, and 12 months after treatment commencement. Results: Serum Zn tended to decrease at one week and one month, and tended to increase during 10 to 12 months. Serum Cu maintained during zero to eight months, then decreased at 10 and 12 months. Serum Fe gradually increased after four months. Serum Mg sharply increased at one week, then decreased further. Grip strength increased for two months, then slightly decreased and maintained 4 to 12 months. eGFR almost maintained for zero to eight months, then slightly decreased thereafter. L-BMD values significantly increased at eight (5.8%) (p < 0.01) and 12 months (9.8%) (p < 0.01). H-BMD increased during the period (at 12 months: 3.7%). Conclusions: These results suggest that at later phases of denosumab therapy, Zn and Fe tended to increase while Mg tended to decrease, all of which are important for bone metabolism. Thus, denosumab might improve Zn and Fe metabolism, and thereby likely increase BMD. Since denosumab may not improve Mg, it is better to obtain Mg supplementation during the therapy.

show abstract

Dietary magnesium intake and fracture risk: data from a large prospective study

Cited by 55 publications

References 29 publications

Magnesium and Human Health: Perspectives and Research Directions

Magnesium and Human Health: Perspectives and Research Directions

Nutrients and Dietary Patterns Related to Osteoporosis

Changes of Bone-Related Minerals during Denosumab Administration in Post-Menopausal Osteoporotic Patients

Contact Info

Product

Resources

About